Skip to main content
. 2021 Apr 2;24:743–754. doi: 10.1016/j.omtn.2021.03.020

Figure 6.

Figure 6

FABP4 inhibitor BMS309403 ameliorates PE clinical phenotypes and Treg/Th17 imbalance of in vivo

(A) The blood pressure of control and PE mice (control, n = 6; L-NAME+vehicle, n = 10; L-NAME+BMS309403 n = 10). (B) The urine protein levels of control and PE mice (control, n = 6; L-NAME+vehicle, n = 10; L-NAME+BMS309403, n = 10). (C) The fetus numbers of control and PE mice (control, n = 6; L-NAME+vehicle, n = 10; L-NAME+BMS309403, n = 10). (D and E) The percentage of Tregs (D) or Th17 cells (E) was assessed by FACS. (F) The immunoreactivities of IL-17A and IL-23 in placental tissues were detected by IHC analysis. (G and H) The serum levels of IL-17A (G) and IL-23 (H) were determined by ELISA. (I) The protein levels of NLRP3 inflammasome components were determined by western blot. Data are expressed as representative images or the mean ± SD of n = 3 experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.